Huang Pei-Yu, Guo Shan-Shan, Zhang Yu, Lu Jia-Bin, Chen Qiu-Yan, Tang Lin-Quan, Zhang Lu, Liu Li-Ting, Zhang Li, Mai Hai-Qiang
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Oncotarget. 2016 Mar 15;7(11):13060-8. doi: 10.18632/oncotarget.7421.
The expression levels of CTLA-4 and CD28 were analyzed in 191 nasopharyngeal carcinoma (NPC) patients diagnosed and treated at our hospital between January 2010 and November 2011. The 3-year overall survival (OS) rate (91.4% vs. 81.2%,p = 0.043), failure-free survival (FFS) rate (82.8% vs. 68.0%, p = 0.009) and distant failure-free survival (D-FFS) rate (85.8% vs. 72.3%, p = 0.006) in the low tumor CTLA-4 expression group was higher than in the high tumor CTLA-4 group. There were no differences between the locoregional failure-free survival (LR-FFS) rates in the high and low tumor CTLA-4 expression groups. Moreover, no differences in the OS, FFS, D-FFS, or LR-FFS were observed between the groups with high and low lymphocyte CTLA-4 levels, high and low tumor CD28 levels, or high and low lymphocyte CD28 levels. Cox regression analysis confirmed the prognostic value of tumor CTLA-4 expression, particularly for D-FFS, in NPC patients (p = 0.044). NPC patients with high tumor CTLA-4 expression had a poorer prognosis than those with low expression.
2010年1月至2011年11月期间，对在我院诊断和治疗的191例鼻咽癌（NPC）患者的细胞毒性T淋巴细胞相关抗原4（CTLA-4）和CD28表达水平进行了分析。肿瘤CTLA-4低表达组的3年总生存率（OS）（91.4%对81.2%，p = 0.043）、无失败生存率（FFS）（82.8%对68.0%，p = 0.009）和远处无失败生存率（D-FFS）（85.8%对72.3%，p = 0.006）高于肿瘤CTLA-4高表达组。肿瘤CTLA-4高表达组和低表达组的局部区域无失败生存率（LR-FFS）无差异。此外，淋巴细胞CTLA-4水平高和低的组、肿瘤CD28水平高和低的组或淋巴细胞CD28水平高和低的组之间，在OS、FFS、D-FFS或LR-FFS方面均未观察到差异。Cox回归分析证实了肿瘤CTLA-4表达在NPC患者中的预后价值，特别是对D-FFS（p = 0.044）。肿瘤CTLA-4高表达的NPC患者预后比低表达患者差。
